{Reference Type}: Meta-Analysis
{Title}: GLP-1 analogs and regional adiposity: A systematic review and meta-analysis.
{Author}: Akoumianakis I;Zagaliotis A;Konstantaraki M;Filippatos TD;
{Journal}: Obes Rev
{Volume}: 24
{Issue}: 8
{Year}: 2023 08 16
{Factor}: 10.867
{DOI}: 10.1111/obr.13574
{Abstract}: Glucagon-like peptide 1 (GLP-1) analogs regulate body weight and liver steatosis. Different body adipose tissue (AT) depots exhibit biological variability. Accordingly, GLP-1 analog effects on AT distribution are unclear.<BR>To investigate GLP1-analog effects on adiposity distribution.<BR>PubMed, Cochrane, and Scopus databases were screened for eligible randomized human trials. Pre-defined endpoints included visceral AT (VAT), subcutaneous AT (SAT), total AT (TAT), epicardial AT (EAT), liver AT (LAT), and waist-to-hip ratio (W:H). Search was conducted until May 17, 2022.<BR>Data extraction and bias assessment were performed by two independent investigators. Treatment effects were estimated using random effects models. Analyses were performed on Review Manager v5.3.<BR>Out of the 367 screened studies, 45 were included in the systematic review and 35 were used in the meta-analysis. GLP-1 analogs reduced VAT, SAT, TAT, LAT, and EAT, with non-significant effects on W:H. Overall bias risk was low.<BR>GLP-1 analog treatment reduces TAT, affecting most studied AT depots, including the pathogenic VAT, EAT, and LAT. GLP-1 analogs may have significant roles in combating metabolic, obesity-associated diseases via reductions of key AT depot volumes.